Triphenylacetic acid (TPAA) is a white crystalline solid that is commonly used as a building block for pharmaceuticals and other organic compounds. It is synthesized through a Friedel-Crafts acylation reaction using benzoyl chloride and benzene. TPAA exhibits anti-inflammatory and anti-cancer properties. Due to its unique structural features, it has been studied for its potential to inhibit the growth of cancer cells and regulate various biological processes. The compound has also been investigated for its applications in polymer chemistry and as a catalyst in organic reactions.'
| ID Source | ID |
|---|---|
| PubMed CID | 68992 |
| CHEMBL ID | 271207 |
| SCHEMBL ID | 45520 |
| MeSH ID | M0142724 |
| Synonym |
|---|
| AKOS005439331 |
| BB 0261888 |
| benzeneacetic acid, .alpha.,.alpha.-diphenyl- |
| 2,2,2-triphenylacetic acid , |
| acetic acid, triphenyl- |
| nsc61 |
| benzeneacetic acid,.alpha.-diphenyl- |
| nsc-61 |
| triphenylacetic acid |
| .alpha.-toluic acid,.alpha.-diphenyl- |
| 595-91-5 |
| triphenylacetic acid, 99% |
| MAYBRIDGE1_006927 |
| STK332019 |
| HMS561C19 |
| CHEMBL271207 , |
| T1585 |
| A832376 |
| 2,2,2-triphenyl-acetic acid |
| nsc 61 |
| amg3vf7ebl , |
| einecs 209-873-4 |
| alpha-toluic acid, alpha,alpha-diphenyl- |
| unii-amg3vf7ebl |
| ai3-05839 |
| benzeneacetic acid, alpha,alpha-diphenyl- |
| bdbm50371393 |
| FT-0632478 |
| tri phenylacetic acid |
| triphenyl acetic acid |
| SCHEMBL45520 |
| J-640276 |
| .alpha.-toluic acid, .alpha.,.alpha.-diphenyl- |
| DTXSID80208204 |
| J-800275 |
| mfcd00004185 |
| CCG-252183 |
| CS-W023181 |
| triphenylessigsa currencyure |
| DS-17416 |
| AMY5473 |
| SY109884 |
| CS1005 |
| 2,2,2-triphenylaceticacid |
| tritylformic acid |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Intermediate conductance calcium-activated potassium channel protein 4 | Homo sapiens (human) | IC50 (µMol) | 10.0000 | 0.0060 | 0.0797 | 0.3600 | AID315276 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| cytosol | Intermediate conductance calcium-activated potassium channel protein 4 | Homo sapiens (human) |
| plasma membrane | Intermediate conductance calcium-activated potassium channel protein 4 | Homo sapiens (human) |
| vesicle | Intermediate conductance calcium-activated potassium channel protein 4 | Homo sapiens (human) |
| voltage-gated potassium channel complex | Intermediate conductance calcium-activated potassium channel protein 4 | Homo sapiens (human) |
| plasma membrane | Intermediate conductance calcium-activated potassium channel protein 4 | Homo sapiens (human) |
| neuronal cell body | Intermediate conductance calcium-activated potassium channel protein 4 | Homo sapiens (human) |
| neuron projection | Intermediate conductance calcium-activated potassium channel protein 4 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID315276 | Inhibition of Gardos channel in human RBC assessed as inhibition of ionomycin-stimulated [86Rb] efflux | 2008 | Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4 | Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (32.55) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||